Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchAndrographolideAndrographol.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Cheminformatics approach to identify andrographolide derivatives as dual inhibitors of methyltransferases (nsp14 and nsp16) of SARS-CoV-2

Thomas et al., Scientific Reports, doi:10.1038/s41598-024-58532-7
Apr 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
In Silico study showing that andrographolide derivatives (PubChem CID 2734589 and 138968421) are potential dual inhibitors of SARS-CoV-2 methyltransferases nsp14 and nsp16, which are crucial for viral replication and evading host immune responses. Authors conducted virtual screening, molecular docking, ADMET profiling, molecular dynamics simulations, free-energy landscape analysis, and density functional theory calculations on 413 andrographolide derivatives. The two lead compounds formed stable complexes with nsp14 and nsp16 proteins via hydrophobic interactions, hydrogen bonds and electrostatic interactions, and had predicted class four toxicity with LD50 values of 500-700 mg/kg. Molecular dynamics simulations and binding free energy calculations confirmed the stability of the protein-ligand complexes.
22 preclinical studies support the efficacy of andrographolide for COVID-19:
Thomas et al., 29 Apr 2024, peer-reviewed, 4 authors. Contact: jsatija11@gmail.com.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperAndrographol..All
Cheminformatics approach to identify andrographolide derivatives as dual inhibitors of methyltransferases (nsp14 and nsp16) of SARS-CoV-2
Jobin Thomas, Anupam Ghosh, Shivendu Ranjan, Jitendra Satija
Scientific Reports, doi:10.1038/s41598-024-58532-7
The Covid-19 pandemic outbreak has accelerated tremendous efforts to discover a therapeutic strategy that targets severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to control viral infection. Various viral proteins have been identified as potential drug targets, however, to date, no specific therapeutic cure is available against the SARS-CoV-2. To address this issue, the present work reports a systematic cheminformatic approach to identify the potent andrographolide derivatives that can target methyltransferases of SARS-CoV-2, i.e. nsp14 and nsp16 which are crucial for the replication of the virus and host immune evasion. A consensus of cheminformatics methodologies including virtual screening, molecular docking, ADMET profiling, molecular dynamics simulations, free-energy landscape analysis, molecular mechanics generalized born surface area (MM-GBSA), and density functional theory (DFT) was utilized. Our study reveals two new andrographolide derivatives (PubChem CID: 2734589 and 138968421) as natural bioactive molecules that can form stable complexes with both proteins via hydrophobic interactions, hydrogen bonds and electrostatic interactions. The toxicity analysis predicts class four toxicity for both compounds with LD 50 value in the range of 500-700 mg/kg. MD simulation reveals the stable formation of the complex for both the compounds and their average trajectory values were found to be lower than the control inhibitor and protein alone. MMGBSA analysis corroborates the MD simulation result and showed the lowest energy for the compounds 2734589 and 138968421. The DFT and MEP analysis also predicts the better reactivity and stability of both the hit compounds. Overall, both andrographolide derivatives exhibit good potential as potent inhibitors for both nsp14 and nsp16 proteins, however, in-vitro and in vivo assessment would be required to prove their efficacy and safety in clinical settings. Moreover, the drug discovery strategy aiming at the dual target approach might serve as a useful model for inventing novel drug molecules for various other diseases.
Author contributions J.T. and J.S. contributed to the study conceptualization and design and were involved in material preparation, data collection and analysis. A.G. and S.R. were involved in molecular dynamics simulations study for providing computational server access. The initial main draft of the manuscript was written by J.T., with additions and revisions from J.S. and S.R. All the authors read and approved the final manuscript. Competing interests The authors declare no competing interests. Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Abraham, GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers, SoftwareX
Baell, Holloway, New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays, J. Med. Chem
Banerjee, Eckert, Schrey, Preissner, ProTox-II: A webserver for the prediction of toxicity of chemicals, Nucleic Acids Res
Becares, Mutagenesis of coronavirus nsp14 reveals its potential role in modulation of the innate immune response, J. Virol
Chandra, Chaudhary, Qamar, Singh, Nain, In silico identification and validation of natural antiviral compounds as potential inhibitors of SARS-CoV-2 methyltransferase, J. Biomol. Struct. Dyn
Chen, Zhang, Li, Han, Probing ligand-binding modes and binding mechanisms of benzoxazole-based amide inhibitors with soluble epoxide hydrolase by molecular docking and molecular dynamics simulation, J. Phys. Chem. B
Czarna, Refolding of lid subdomain of SARS-CoV-2 nsp14 upon nsp10 interaction releases exonuclease activity, Structure
Dennington, Keith, Millam, Inc, Shawnee Mission et al., None, Version
Dyall, Middle east respiratory syndrome and severe acute respiratory syndrome: Current therapeutic options and potential targets for novel therapies, Drugs
Hanna, Informatics and computational approaches for the discovery and optimization of natural product-inspired inhibitors of the SARS-CoV-2 2′-O-methyltransferase, J. Nat. Prod
Hossain, Urbi, Sule, Rahman, Andrographis Paniculata (burm et al., ex Nees: A review of ethnobotany, phytochemistry, and pharmacology, Sci. World J
Hosseini, Askari, A review of neurological side effects of Covid-19 vaccination, Eur. J. Med. Res
Huang, CHARMM36m: An improved force field for folded and intrinsically disordered proteins, Nat. Methods
Jain, Satija, Sudandiradoss, Discovery of andrographolide hit analog as a potent cyclooxygenase-2 inhibitor through consensus MD-simulation, electrostatic potential energy simulation and ligand efficiency metrics, Sci. Rep
Joshi, Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease, J. Biomol. Struct. Dyn, doi:10.1080/07391102.2020.1760137
Kadioglu, Saeed, Greten, Efferth, Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning, Comput. Biol. Med
Kumar, Extraction, isolation, synthesis, and biological evaluation of novel piperic acid derivatives for the treatment of Alzheimer's disease, Mol. Divers, doi:10.1007/s11030-023-10667-x
Kumar, Identification and structural studies of natural inhibitors against SARS-CoV-2 viral RNA methyltransferase (NSP16), J. Biomol. Struct. Dyn
Laksmiani, Active compounds activity from the medicinal plants against SARS-CoV-2 using in silico assay, Biomed. Pharmacol. J
Li, Hilgenfeld, Whitley, De Clercq, Therapeutic strategies for Covid-19: Progress and lessons learned, Nat. Rev. Drug Discov
Li, Probing ligand binding modes of human cytochrome P450 2J2 by homology modeling, molecular dynamics simulation, and flexible molecular docking, Proteins Struct. Funct. Bioinform
Livingston, Bucher, Rekito, Coronavirus disease 2019 and influenza 2019-2020, JAMA
Moeller, Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN, Proc. Natl. Acad. Sci. U. S. A
Morris, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J. Comput. Chem
Murugan, Pandian, Jeyakanthan, Computational investigation on Andrographis paniculata phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known antiviral compounds in drug trials, J. Biomol. Struct. Dyn
Newman, Drug delivery to the lungs: Challenges and opportunities, Ther. Deliv
O'boyle, Open Babel: An Open chemical toolbox, J. Cheminform
Pholphana, Rangkadilok, Saehun, Ritruechai, Satayavivad, Changes in the contents of four active diterpenoids at different growth stages in Andrographis paniculata (Burm.f.) Nees (Chuanxinlian), Chin. Med. (United Kingdom)
Rai, Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: An effort toward drug repurposing to combat Covid-19, Mol. Divers
Robson, Bioinformatics studies on a function of the SARS-CoV-2 spike glycoprotein as the binding of host sialic acid glycans, Comput. Biol. Med
Romano, Ruggiero, Squeglia, Maga, Berisio, A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping, Cells
Rosas-Lemus, High-resolution structures of the SARS-CoV-2 2′-O-methyltransferase reveal strategies for structure-based inhibitor design, Sci. Signal
Shi, Wen, Song, Wang, Yu, Computational investigation of potent inhibitors against SARS-CoV-2 2′-O-methyltransferase (nsp16): Structure-based pharmacophore modeling, molecular docking, molecular dynamics simulations and binding free energy calculations, J. Mol. Graph. Model
Tahir, Coronavirus genomic nsp14-ExoN, structure, role, mechanism, and potential application as a drug target, J. Med. Virol
Thomas, Kumar, Satija, Integrated molecular and quantum mechanical approach to identify novel potent natural bioactive compound against 2′-O-methyltransferase (nsp16) of SARS-CoV-2, J. Biomol. Struct. Dyn
Trott, Olson, AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading, J. Comput. Chem
Valdés-Tresanco, Valdés-Tresanco, Valiente, Moreno, Gmx_Mmpbsa, A new tool to perform end-state free energy calculations with GROMACS, J. Chem. Theory Comput
Viswanathan, Structural basis of RNA cap modification by SARS-CoV-2, Nat. Commun
Wu, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm. Sin. B
Yap, PaDEL-descriptor: An open source software to calculate molecular descriptors and fingerprints, J. Comput. Chem
Zheng, SARS-coV-2: An emerging coronavirus that causes a global threat, Int. J. Biol. Sci
Zmudzinski, Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PLpro and Mpro proteases, and nsp14 guanine N7-methyltransferase, Sci. Rep
{ 'indexed': {'date-parts': [[2024, 4, 30]], 'date-time': '2024-04-30T00:26:52Z', 'timestamp': 1714436812836}, 'reference-count': 42, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2024, 4, 29]], 'date-time': '2024-04-29T00:00:00Z', 'timestamp': 1714348800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2024, 4, 29]], 'date-time': '2024-04-29T00:00:00Z', 'timestamp': 1714348800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>The Covid-19 pandemic outbreak has accelerated ' 'tremendous efforts to discover a therapeutic strategy that targets severe acute respiratory ' 'syndrome coronavirus 2 (SARS-CoV-2) to control viral infection. Various viral proteins have ' 'been identified as potential drug targets, however, to date, no specific therapeutic cure is ' 'available against the SARS-CoV-2. To address this issue, the present work reports a ' 'systematic cheminformatic approach to identify the potent andrographolide derivatives that ' 'can target methyltransferases of SARS-CoV-2, i.e. nsp14 and nsp16 which are crucial for the ' 'replication of the virus and host immune evasion. A consensus of cheminformatics ' 'methodologies including virtual screening, molecular docking, ADMET profiling, molecular ' 'dynamics simulations, free-energy landscape analysis, molecular mechanics generalized born ' 'surface area (MM-GBSA), and density functional theory (DFT) was utilized. Our study reveals ' 'two new andrographolide derivatives (PubChem CID: 2734589 and 138968421) as natural bioactive ' 'molecules that can form stable complexes with both proteins via hydrophobic interactions, ' 'hydrogen bonds and electrostatic interactions. The toxicity analysis predicts class four ' 'toxicity for both compounds with LD<jats:sub>50</jats:sub> value in the range of 500–700\xa0' 'mg/kg. MD simulation reveals the stable formation of the complex for both the compounds and ' 'their average trajectory values were found to be lower than the control inhibitor and protein ' 'alone. MMGBSA analysis corroborates the MD simulation result and showed the lowest energy for ' 'the compounds 2734589 and 138968421. The DFT and MEP analysis also predicts the better ' 'reactivity and stability of both the hit compounds. Overall, both andrographolide derivatives ' 'exhibit good potential as potent inhibitors for both nsp14 and nsp16 proteins, however, ' 'in-vitro and in vivo assessment would be required to prove their efficacy and safety in ' 'clinical settings. Moreover, the drug discovery strategy aiming at the dual target approach ' 'might serve as a useful model for inventing novel drug molecules for various other ' 'diseases.</jats:p>', 'DOI': '10.1038/s41598-024-58532-7', 'type': 'journal-article', 'created': {'date-parts': [[2024, 4, 29]], 'date-time': '2024-04-29T11:03:01Z', 'timestamp': 1714388581000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Cheminformatics approach to identify andrographolide derivatives as dual inhibitors of ' 'methyltransferases (nsp14 and nsp16) of SARS-CoV-2', 'prefix': '10.1038', 'volume': '14', 'author': [ {'given': 'Jobin', 'family': 'Thomas', 'sequence': 'first', 'affiliation': []}, {'given': 'Anupam', 'family': 'Ghosh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shivendu', 'family': 'Ranjan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jitendra', 'family': 'Satija', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2024, 4, 29]]}, 'reference': [ { 'key': '58532_CR1', 'doi-asserted-by': 'publisher', 'first-page': '1122', 'DOI': '10.1001/jama.2020.2633', 'volume': '323', 'author': 'E Livingston', 'year': '2020', 'unstructured': 'Livingston, E., Bucher, K. & Rekito, A. Coronavirus disease 2019 and ' 'influenza 2019–2020. JAMA 323, 1122–1122 (2020).', 'journal-title': 'JAMA'}, { 'key': '58532_CR2', 'doi-asserted-by': 'publisher', 'first-page': '1935', 'DOI': '10.1007/s40265-017-0830-1', 'volume': '77', 'author': 'J Dyall', 'year': '2017', 'unstructured': 'Dyall, J. et al. Middle east respiratory syndrome and severe acute ' 'respiratory syndrome: Current therapeutic options and potential targets ' 'for novel therapies. Drugs 77, 1935–1966 (2017).', 'journal-title': 'Drugs'}, { 'key': '58532_CR3', 'doi-asserted-by': 'publisher', 'first-page': '1678', 'DOI': '10.7150/ijbs.45053', 'volume': '16', 'author': 'J Zheng', 'year': '2020', 'unstructured': 'Zheng, J. SARS-coV-2: An emerging coronavirus that causes a global ' 'threat. Int. J. Biol. Sci. 16, 1678–1685 (2020).', 'journal-title': 'Int. J. Biol. Sci.'}, { 'key': '58532_CR4', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1186/s40001-023-00992-0', 'volume': '28', 'author': 'R Hosseini', 'year': '2023', 'unstructured': 'Hosseini, R. & Askari, N. A review of neurological side effects of ' 'Covid-19 vaccination. Eur. J. Med. Res. 28, 1–8 (2023).', 'journal-title': 'Eur. J. Med. Res.'}, { 'key': '58532_CR5', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.compbiomed.2020.103849', 'volume': '122', 'author': 'B Robson', 'year': '2020', 'unstructured': 'Robson, B. Bioinformatics studies on a function of the SARS-CoV-2 spike ' 'glycoprotein as the binding of host sialic acid glycans. Comput. Biol. ' 'Med. 122, 103849 (2020).', 'journal-title': 'Comput. Biol. Med.'}, { 'key': '58532_CR6', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/07391102.2020.1760137', 'author': 'RS Joshi', 'year': '2020', 'unstructured': 'Joshi, R. S. et al. Discovery of potential multi-target-directed ligands ' 'by targeting host-specific SARS-CoV-2 structurally conserved main ' 'protease. J. Biomol. Struct. Dyn. ' 'https://doi.org/10.1080/07391102.2020.1760137 (2020).', 'journal-title': 'J. Biomol. Struct. Dyn.'}, { 'key': '58532_CR7', 'doi-asserted-by': 'publisher', 'first-page': '1905', 'DOI': '10.1007/s11030-021-10188-5', 'volume': '25', 'author': 'H Rai', 'year': '2021', 'unstructured': 'Rai, H. et al. Molecular docking, binding mode analysis, molecular ' 'dynamics, and prediction of ADMET/toxicity properties of selective ' 'potential antiviral agents against SARS-CoV-2 main protease: An effort ' 'toward drug repurposing to combat Covid-19. Mol. Divers. 25, 1905–1927 ' '(2021).', 'journal-title': 'Mol. Divers.'}, { 'key': '58532_CR8', 'doi-asserted-by': 'publisher', 'first-page': '766', 'DOI': '10.1016/j.apsb.2020.02.008', 'volume': '10', 'author': 'C Wu', 'year': '2020', 'unstructured': 'Wu, C. et al. Analysis of therapeutic targets for SARS-CoV-2 and ' 'discovery of potential drugs by computational methods. Acta Pharm. Sin. ' 'B 10, 766–788 (2020).', 'journal-title': 'Acta Pharm. Sin. B'}, { 'key': '58532_CR9', 'doi-asserted-by': 'publisher', 'first-page': '449', 'DOI': '10.1038/s41573-023-00672-y', 'volume': '22', 'author': 'G Li', 'year': '2023', 'unstructured': 'Li, G., Hilgenfeld, R., Whitley, R. & De Clercq, E. Therapeutic ' 'strategies for Covid-19: Progress and lessons learned. Nat. Rev. Drug ' 'Discov. 22, 449–475 (2023).', 'journal-title': 'Nat. Rev. Drug Discov.'}, { 'key': '58532_CR10', 'doi-asserted-by': 'publisher', 'first-page': '1999', 'DOI': '10.1080/07391102.2023.2206287', 'volume': '42', 'author': 'J Thomas', 'year': '2023', 'unstructured': 'Thomas, J., Kumar, S. & Satija, J. Integrated molecular and quantum ' 'mechanical approach to identify novel potent natural bioactive compound ' 'against 2′-O-methyltransferase (nsp16) of SARS-CoV-2. J. Biomol. Struct. ' 'Dyn. 42, 1999–2012 (2023).', 'journal-title': 'J. Biomol. Struct. Dyn.'}, { 'key': '58532_CR11', 'doi-asserted-by': 'publisher', 'first-page': '13965', 'DOI': '10.1080/07391102.2021.1997821', 'volume': '40', 'author': 'M Kumar', 'year': '2021', 'unstructured': 'Kumar, M. et al. Identification and structural studies of natural ' 'inhibitors against SARS-CoV-2 viral RNA methyltransferase (NSP16). J. ' 'Biomol. Struct. Dyn. 40, 13965–13975 (2021).', 'journal-title': 'J. Biomol. Struct. Dyn.'}, { 'key': '58532_CR12', 'doi-asserted-by': 'publisher', 'first-page': '4258', 'DOI': '10.1002/jmv.27009', 'volume': '93', 'author': 'M Tahir', 'year': '2021', 'unstructured': 'Tahir, M. Coronavirus genomic nsp14-ExoN, structure, role, mechanism, ' 'and potential application as a drug target. J. Med. Virol. 93, 4258–4264 ' '(2021).', 'journal-title': 'J. Med. Virol.'}, { 'key': '58532_CR13', 'doi-asserted-by': 'publisher', 'DOI': '10.1073/pnas.2106379119', 'volume': '119', 'author': 'NH Moeller', 'year': '2022', 'unstructured': 'Moeller, N. H. et al. Structure and dynamics of SARS-CoV-2 proofreading ' 'exoribonuclease ExoN. Proc. Natl. Acad. Sci. U. S. A. 119, e2106379119 ' '(2022).', 'journal-title': 'Proc. Natl. Acad. Sci. U. S. A.'}, { 'key': '58532_CR14', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1038/s41467-020-17496-8', 'volume': '11', 'author': 'T Viswanathan', 'year': '2020', 'unstructured': 'Viswanathan, T. et al. Structural basis of RNA cap modification by ' 'SARS-CoV-2. Nat. Commun. 11, 1–7 (2020).', 'journal-title': 'Nat. Commun.'}, { 'key': '58532_CR15', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1038/s41598-023-35907-w', 'volume': '13', 'author': 'M Zmudzinski', 'year': '2023', 'unstructured': 'Zmudzinski, M. et al. Ebselen derivatives inhibit SARS-CoV-2 replication ' 'by inhibition of its essential proteins: PLpro and Mpro proteases, and ' 'nsp14 guanine N7-methyltransferase. Sci. Rep. 13, 1–16 (2023).', 'journal-title': 'Sci. Rep.'}, { 'key': '58532_CR16', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jmgm.2022.108306', 'volume': '117', 'author': 'L Shi', 'year': '2022', 'unstructured': 'Shi, L., Wen, Z., Song, Y., Wang, J. & Yu, D. Computational ' 'investigation of potent inhibitors against SARS-CoV-2 ' '2′-O-methyltransferase (nsp16): Structure-based pharmacophore modeling, ' 'molecular docking, molecular dynamics simulations and binding free ' 'energy calculations. J. Mol. Graph. Model. 117, 108306 (2022).', 'journal-title': 'J. Mol. Graph. Model.'}, { 'key': '58532_CR17', 'doi-asserted-by': 'publisher', 'first-page': '217', 'DOI': '10.1021/acs.jnatprod.3c00875', 'volume': '87', 'author': 'GS Hanna', 'year': '2023', 'unstructured': 'Hanna, G. S. et al. Informatics and computational approaches for the ' 'discovery and optimization of natural product-inspired inhibitors of the ' 'SARS-CoV-2 2′-O-methyltransferase. J. Nat. Prod. 87, 217–227 (2023).', 'journal-title': 'J. Nat. Prod.'}, { 'key': '58532_CR18', 'doi-asserted-by': 'publisher', 'first-page': '6534', 'DOI': '10.1080/07391102.2021.1886174', 'volume': '40', 'author': 'A Chandra', 'year': '2022', 'unstructured': 'Chandra, A., Chaudhary, M., Qamar, I., Singh, N. & Nain, V. In silico ' 'identification and validation of natural antiviral compounds as ' 'potential inhibitors of SARS-CoV-2 methyltransferase. J. Biomol. Struct. ' 'Dyn. 40, 6534–6544 (2022).', 'journal-title': 'J. Biomol. Struct. Dyn.'}, { 'key': '58532_CR19', 'first-page': '1', 'volume': '8', 'author': 'N Pholphana', 'year': '2013', 'unstructured': 'Pholphana, N., Rangkadilok, N., Saehun, J., Ritruechai, S. & ' 'Satayavivad, J. Changes in the contents of four active diterpenoids at ' 'different growth stages in Andrographis paniculata (Burm.f.) Nees ' '(Chuanxinlian). Chin. Med. (United Kingdom) 8, 1–12 (2013).', 'journal-title': 'Chin. Med. (United Kingdom)'}, { 'key': '58532_CR20', 'doi-asserted-by': 'publisher', 'first-page': '274905', 'DOI': '10.1155/2014/274905', 'volume': '2014', 'author': 'MS Hossain', 'year': '2014', 'unstructured': 'Hossain, M. S., Urbi, Z., Sule, A. & Rahman, K. M. H. Andrographis ' 'paniculata (Burm. f.) Wall. ex Nees: A review of ethnobotany, ' 'phytochemistry, and pharmacology. Sci. World J. 2014, 274905 (2014).', 'journal-title': 'Sci. World J.'}, { 'key': '58532_CR21', 'doi-asserted-by': 'publisher', 'first-page': '4415', 'DOI': '10.1080/07391102.2020.1777901', 'volume': '39', 'author': 'NA Murugan', 'year': '2020', 'unstructured': 'Murugan, N. A., Pandian, C. J. & Jeyakanthan, J. Computational ' 'investigation on Andrographis paniculata phytochemicals to evaluate ' 'their potency against SARS-CoV-2 in comparison to known antiviral ' 'compounds in drug trials. J. Biomol. Struct. Dyn. 39, 4415–4426 (2020).', 'journal-title': 'J. Biomol. Struct. Dyn.'}, { 'key': '58532_CR22', 'doi-asserted-by': 'publisher', 'first-page': '8147', 'DOI': '10.1038/s41598-023-35192-7', 'volume': '13', 'author': 'P Jain', 'year': '2023', 'unstructured': 'Jain, P., Satija, J. & Sudandiradoss, C. Discovery of andrographolide ' 'hit analog as a potent cyclooxygenase-2 inhibitor through consensus ' 'MD-simulation, electrostatic potential energy simulation and ligand ' 'efficiency metrics. Sci. Rep. 13, 8147 (2023).', 'journal-title': 'Sci. Rep.'}, { 'key': '58532_CR23', 'doi-asserted-by': 'publisher', 'first-page': '873', 'DOI': '10.13005/bpj/1953', 'volume': '13', 'author': 'NP Linda Laksmiani', 'year': '2020', 'unstructured': 'Linda Laksmiani, N. P. et al. Active compounds activity from the ' 'medicinal plants against SARS-CoV-2 using in silico assay. Biomed. ' 'Pharmacol. J. 13, 873–881 (2020).', 'journal-title': 'Biomed. Pharmacol. J.'}, { 'key': '58532_CR24', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.compbiomed.2021.104359', 'volume': '133', 'author': 'O Kadioglu', 'year': '2021', 'unstructured': 'Kadioglu, O., Saeed, M., Greten, H. J. & Efferth, T. Identification of ' 'novel compounds against three targets of SARS CoV-2 coronavirus by ' 'combined virtual screening and supervised machine learning. Comput. ' 'Biol. Med. 133, 104359 (2021).', 'journal-title': 'Comput. Biol. Med.'}, { 'key': '58532_CR25', 'doi-asserted-by': 'publisher', 'first-page': '1050', 'DOI': '10.1016/j.str.2022.04.014', 'volume': '30', 'author': 'A Czarna', 'year': '2022', 'unstructured': 'Czarna, A. et al. Refolding of lid subdomain of SARS-CoV-2 nsp14 upon ' 'nsp10 interaction releases exonuclease activity. Structure 30, 1050–1054 ' '(2022).', 'journal-title': 'Structure'}, { 'key': '58532_CR26', 'doi-asserted-by': 'publisher', 'first-page': '1202', 'DOI': '10.1126/scisignal.abe1202', 'volume': '13', 'author': 'M Rosas-Lemus', 'year': '2020', 'unstructured': 'Rosas-Lemus, M. et al. High-resolution structures of the SARS-CoV-2 ' '2′-O-methyltransferase reveal strategies for structure-based inhibitor ' 'design. Sci. Signal. 13, 1202 (2020).', 'journal-title': 'Sci. Signal.'}, { 'key': '58532_CR27', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1186/1758-2946-3-1', 'volume': '3', 'author': 'NM O’Boyle', 'year': '2011', 'unstructured': 'O’Boyle, N. M. et al. Open Babel: An Open chemical toolbox. J. ' 'Cheminform. 3, 1–14 (2011).', 'journal-title': 'J. Cheminform.'}, { 'key': '58532_CR28', 'doi-asserted-by': 'publisher', 'first-page': '455', 'DOI': '10.1002/jcc.21334', 'volume': '31', 'author': 'O Trott', 'year': '2010', 'unstructured': 'Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy ' 'of docking with a new scoring function, efficient optimization and ' 'multithreading. J. Comput. Chem. 31, 455–461 (2010).', 'journal-title': 'J. Comput. Chem.'}, { 'key': '58532_CR29', 'doi-asserted-by': 'publisher', 'first-page': '5399', 'DOI': '10.1128/JVI.03259-15', 'volume': '90', 'author': 'M Becares', 'year': '2016', 'unstructured': 'Becares, M. et al. Mutagenesis of coronavirus nsp14 reveals its ' 'potential role in modulation of the innate immune response. J. Virol. ' '90, 5399–5414 (2016).', 'journal-title': 'J. Virol.'}, { 'key': '58532_CR30', 'doi-asserted-by': 'publisher', 'first-page': '1267', 'DOI': '10.3390/cells9051267', 'volume': '9', 'author': 'M Romano', 'year': '2020', 'unstructured': 'Romano, M., Ruggiero, A., Squeglia, F., Maga, G. & Berisio, R. A ' 'structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, ' 'proofreading and final capping. Cells 9, 1267 (2020).', 'journal-title': 'Cells'}, { 'key': '58532_CR31', 'doi-asserted-by': 'publisher', 'first-page': '2785', 'DOI': '10.1002/jcc.21256', 'volume': '30', 'author': 'GM Morris', 'year': '2009', 'unstructured': 'Morris, G. M. et al. AutoDock4 and AutoDockTools4: Automated docking ' 'with selective receptor flexibility. J. Comput. Chem. 30, 2785–2791 ' '(2009).', 'journal-title': 'J. Comput. Chem.'}, { 'key': '58532_CR32', 'doi-asserted-by': 'publisher', 'first-page': '1466', 'DOI': '10.1002/jcc.21707', 'volume': '32', 'author': 'CW Yap', 'year': '2011', 'unstructured': 'Yap, C. W. PaDEL-descriptor: An open source software to calculate ' 'molecular descriptors and fingerprints. J. Comput. Chem. 32, 1466–1474 ' '(2011).', 'journal-title': 'J. Comput. Chem.'}, { 'key': '58532_CR33', 'doi-asserted-by': 'publisher', 'first-page': 'W257', 'DOI': '10.1093/nar/gky318', 'volume': '46', 'author': 'P Banerjee', 'year': '2018', 'unstructured': 'Banerjee, P., Eckert, A. O., Schrey, A. K. & Preissner, R. ProTox-II: A ' 'webserver for the prediction of toxicity of chemicals. Nucleic Acids ' 'Res. 46, W257–W263 (2018).', 'journal-title': 'Nucleic Acids Res.'}, { 'key': '58532_CR34', 'doi-asserted-by': 'publisher', 'first-page': '2719', 'DOI': '10.1021/jm901137j', 'volume': '53', 'author': 'JB Baell', 'year': '2010', 'unstructured': 'Baell, J. B. & Holloway, G. A. New substructure filters for removal of ' 'pan assay interference compounds (PAINS) from screening libraries and ' 'for their exclusion in bioassays. J. Med. Chem. 53, 2719–2740 (2010).', 'journal-title': 'J. Med. Chem.'}, { 'key': '58532_CR35', 'doi-asserted-by': 'publisher', 'first-page': '19', 'DOI': '10.1016/j.softx.2015.06.001', 'volume': '1–2', 'author': 'MJ Abraham', 'year': '2015', 'unstructured': 'Abraham, M. J. et al. GROMACS: High performance molecular simulations ' 'through multi-level parallelism from laptops to supercomputers. ' 'SoftwareX 1–2, 19–25 (2015).', 'journal-title': 'SoftwareX'}, { 'key': '58532_CR36', 'doi-asserted-by': 'publisher', 'first-page': '71', 'DOI': '10.1038/nmeth.4067', 'volume': '14', 'author': 'J Huang', 'year': '2016', 'unstructured': 'Huang, J. et al. CHARMM36m: An improved force field for folded and ' 'intrinsically disordered proteins. Nat. Methods 14, 71–73 (2016).', 'journal-title': 'Nat. Methods'}, { 'key': '58532_CR37', 'doi-asserted-by': 'publisher', 'first-page': '6281', 'DOI': '10.1021/acs.jctc.1c00645', 'volume': '17', 'author': 'MS Valdés-Tresanco', 'year': '2021', 'unstructured': 'Valdés-Tresanco, M. S., Valdés-Tresanco, M. E., Valiente, P. A. & ' 'Moreno, E. Gmx_MMPBSA: A new tool to perform end-state free energy ' 'calculations with GROMACS. J. Chem. Theory Comput. 17, 6281–6291 (2021).', 'journal-title': 'J. Chem. Theory Comput.'}, { 'key': '58532_CR38', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s11030-023-10667-x', 'author': 'J Kumar', 'year': '2023', 'unstructured': 'Kumar, J. et al. Extraction, isolation, synthesis, and biological ' 'evaluation of novel piperic acid derivatives for the treatment of ' 'Alzheimer’s disease. Mol. Divers. ' 'https://doi.org/10.1007/s11030-023-10667-x (2023).', 'journal-title': 'Mol. Divers.'}, { 'key': '58532_CR39', 'first-page': '1', 'volume': '6', 'author': 'R Dennington', 'year': '2016', 'unstructured': 'Dennington, R., Keith, T. A., Millam, J. M., Inc, S. & Shawnee Mission, ' 'K. S. GaussView. Version 6, 1 (2016).', 'journal-title': 'Version'}, { 'key': '58532_CR40', 'doi-asserted-by': 'publisher', 'first-page': '647', 'DOI': '10.4155/tde-2017-0037', 'volume': '8', 'author': 'SP Newman', 'year': '2017', 'unstructured': 'Newman, S. P. Drug delivery to the lungs: Challenges and opportunities. ' 'Ther. Deliv. 8, 647–661 (2017).', 'journal-title': 'Ther. Deliv.'}, { 'key': '58532_CR41', 'doi-asserted-by': 'publisher', 'first-page': '10219', 'DOI': '10.1021/jp304736e', 'volume': '116', 'author': 'H Chen', 'year': '2012', 'unstructured': 'Chen, H., Zhang, Y., Li, L. & Han, J. G. Probing ligand-binding modes ' 'and binding mechanisms of benzoxazole-based amide inhibitors with ' 'soluble epoxide hydrolase by molecular docking and molecular dynamics ' 'simulation. J. Phys. Chem. B 116, 10219–10233 (2012).', 'journal-title': 'J. Phys. Chem. B'}, { 'key': '58532_CR42', 'doi-asserted-by': 'publisher', 'first-page': '938', 'DOI': '10.1002/prot.21778', 'volume': '71', 'author': 'W Li', 'year': '2008', 'unstructured': 'Li, W. et al. Probing ligand binding modes of human cytochrome P450 2J2 ' 'by homology modeling, molecular dynamics simulation, and flexible ' 'molecular docking. Proteins Struct. Funct. Bioinform. 71, 938–949 ' '(2008).', 'journal-title': 'Proteins Struct. Funct. Bioinform.'}], 'container-title': 'Scientific Reports', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.nature.com/articles/s41598-024-58532-7.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41598-024-58532-7', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41598-024-58532-7.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 4, 29]], 'date-time': '2024-04-29T11:03:09Z', 'timestamp': 1714388589000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.nature.com/articles/s41598-024-58532-7'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 4, 29]]}, 'references-count': 42, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2024, 12]]}}, 'alternative-id': ['58532'], 'URL': 'http://dx.doi.org/10.1038/s41598-024-58532-7', 'relation': {}, 'ISSN': ['2045-2322'], 'subject': [], 'container-title-short': 'Sci Rep', 'published': {'date-parts': [[2024, 4, 29]]}, 'assertion': [ { 'value': '22 December 2023', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '1 April 2024', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '29 April 2024', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'The authors declare no competing interests.', 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '9801'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit